Newport
Newport Premium, Global, and Sourcing solutions are used across the globe by generics, API manufacturers, and innovators alike to target products for development and licensing, source active ingredients, and monitor competition.
Whether you want to get the basics and get started fast — or fine tune your skills, Thomson Reuters can help with a variety of targeted training opportunities. Classes are conducted over the internet — some live with open question-and-answer sessions — and others prerecorded so you can take advantage of them at your convenience, around the clock.
We invite you to explore the following Newport training opportunities.
NEWPORT PUBLIC SESSIONS
Getting Started with Newport
How do I best utilize the Newport database? This 60 minute session is geared toward newer users or those seeking a refresher.
Learn about the content and how to best navigate around the database. See how to search for a product and company, and what information is available.
Understand how to best filter, sort and export your data, as well as how to set up email alerts.
- Wednesday January 25, 2012
9 am New York – 2 pm London – 3 pm Paris – 7:30 pm Mumbai
Register - Tuesday, February 14, 2012
9:30 am Paris – 2 pm Mumbai – 4:30 pm Singapore – 7:30 pm Sydney
Register - Wednesday, February 15, 2012
11 am San Francisco – 1 pm Chicago – 2 pm New York– 7 pm London
Register - Wednesday, February 22, 2012
9 am New York – 2 pm London – 3 pm Paris – 7:30 pm Mumbai
Register - Wednesday, March 14, 2012
9 am New York – 1 pm London – 2 pm Paris – 6:30 pm Mumbai
Register - Tuesday, March 20, 2012
11 am San Francisco – 1 pm Chicago – 2 pm New York– 6 pm London
Register
US MARKET SHARE: add-on module
- How has the market share for a product changed as a result of new entrants into the market?
- Which dose forms and strengths are most popular for a particular drug?
- What are the characteristics of the patient population for a particular drug?
Learn about the US Market Share add-on module, which seamlessly integrates with Newport Premium and Newport Global. Get an overview of the content available such as patient characteristics and market share break down in the US by dose from, strength, marketer, as well as brand vs. generic. See how this add-on module can help you analyze the industry dynamics and gain insights into the US pharmaceutical market. Please join us for this 30-minute topic session.
- Thursday, February 16, 2012
9:30 am Paris – 2 pm Mumbai – 4:30 pm Singapore – 7:30 pm Sydney
Register - Thursday, February 23, 2012
11 am San Francisco – 1 pm Chicago – 2 pm New York– 7 pm London
Register - Tuesday, February 28, 2012
9 am New York – 2 pm London – 3 pm Paris – 7:30 pm Mumbai
Register
PHASE III DRUGS: add-on module
- Which molecules are currently in phase III clinical trials?
- Are additional indications and line extensions being pursued for a particular product?
- Are generic industry players already involved with products that have not even been launched yet?
Learn about the Phase III Drugs add-on module which seamlessly integrates with Newport Premium and Newport Global. This module extends the coverage of APIs from approved and/or launched drugs to include compounds in late stage development (phase III, registration, or under review) and provides information on line extensions for already marketed molecules. Learn how this module can help you gain a competitive edge by targeting new opportunities at the earliest possible opportunity. Please join us for this 30-minute topic session.
Newport Recorded Webinar Sessions
Preparing for Paragraph IV Patent Challenges
US Follow-on Biologic Market: Developments and Forecasts
Using Newport to Understand and Track Global Generic Industry Deal-making
Support & Training Materials
Factsheets & Product Pages
- Newport Premium (for generics)
- Newport Premium (for innovators)
In one place, we've gathered the information that can help you enhance your discovery and development activities, and arm your decision-making. Visit our Knowledge Hub to subscribe to our complimentary issues of white papers and quarterly reports.
Feedback